Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Joly

Showing results (541-550 of 569) with videos related to

Pageof 57
Sort By:
The American Journal of Surgical Pathology|October 19, 1999
The Spectrum of Cutaneous Lymphomas in HIV infection: a study of 21 casesM Beylot-Barry, B Vergier, B Masquelier, et al.
The American Journal of Surgical Pathology|February 16, 1999
CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Français d'Etude des Lymphomes Cutanés (GFELC)T Petrella, S Dalac, M Maynadié, et al.
The American Journal of Surgical Pathology|October 20, 1998
Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 casesB Vergier, M Beylot-Barry, K Pulford, et al.
The British Journal of Dermatology|October 17, 2020
International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoidW Masmoudi, M Vaillant, S Vassileva, et al.
Annales De Dermatologie Et De Venereologie|March 31, 2005
[Bullous pemphigoid in young patients: a retrospective study of 74 cases]E Bourdon-Lanoy, J-C Roujeau, P Joly, et al.
The British Journal of Dermatology|January 23, 2016
Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigusC Boulard, S Duvert Lehembre, C Picard-Dahan, et al.
British Journal of Cancer|May 4, 2016
First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanomaC Le Tourneau, B Dreno, Y Kirova, et al.
Dermatology (Basel, Switzerland)|January 20, 2004
Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient seraP Joly, Ph Courville, C Lok, et al.
The British Journal of Dermatology|June 26, 2021
International multicentre observational study to assess the efficacy and safety of a 0·5 mg kg<sup>-1</sup> per day starting dose of oral corticosteroids to treat bullous pemphigoidV Hébert, S Bastos, K Drenovska, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 14, 2017
Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohortE Sbidian, C Giboin, H Bachelez, et al.
Pageof 57

Showing results (541-550 of 569) with videos related to

Sort By:
Pageof 57
The American Journal of Surgical Pathology|October 19, 1999
The Spectrum of Cutaneous Lymphomas in HIV infection: a study of 21 casesM Beylot-Barry, B Vergier, B Masquelier, et al.
The American Journal of Surgical Pathology|February 16, 1999
CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Français d'Etude des Lymphomes Cutanés (GFELC)T Petrella, S Dalac, M Maynadié, et al.
The American Journal of Surgical Pathology|October 20, 1998
Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 casesB Vergier, M Beylot-Barry, K Pulford, et al.
The British Journal of Dermatology|October 17, 2020
International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoidW Masmoudi, M Vaillant, S Vassileva, et al.
Annales De Dermatologie Et De Venereologie|March 31, 2005
[Bullous pemphigoid in young patients: a retrospective study of 74 cases]E Bourdon-Lanoy, J-C Roujeau, P Joly, et al.
The British Journal of Dermatology|January 23, 2016
Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigusC Boulard, S Duvert Lehembre, C Picard-Dahan, et al.
British Journal of Cancer|May 4, 2016
First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanomaC Le Tourneau, B Dreno, Y Kirova, et al.
Dermatology (Basel, Switzerland)|January 20, 2004
Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient seraP Joly, Ph Courville, C Lok, et al.
The British Journal of Dermatology|June 26, 2021
International multicentre observational study to assess the efficacy and safety of a 0·5 mg kg<sup>-1</sup> per day starting dose of oral corticosteroids to treat bullous pemphigoidV Hébert, S Bastos, K Drenovska, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 14, 2017
Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohortE Sbidian, C Giboin, H Bachelez, et al.
Pageof 57